Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY736 (ianalumab) in Rheumatoid Arthritis
NCT02675803Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2010
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing VAY736 with Placebo (2 arms). Primary endpoints: Number of patients with adverse events, Absolute bioavailability of VAY736 at 188 weeks and 7 more. Started Dec 2010; status: completed.
02
Drugs
ianalumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02675803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02675803.